theophylline Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
N-methylated xanthine derivatives 2620 58-55-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • aminophyllin
  • aminophylline
  • theophylline
  • 1,3-Dimethylxanthine
  • armophylline
  • cetraphylline
  • chronophyllin
  • duraphyllin
  • elixophyllin
  • elixophylline
  • etheophyl
  • lanophyllin
  • pseudotheophylline
  • theophyllin
  • throphylline
  • xanthium
  • theophylline anhydrous
  • aminophylline dihydrate
  • theophylline sodium glycinate
  • theophylline monohydrate
A plant genus of the family ASTERACEAE. The name "prickly burweed" is sometimes used but causes confusion with AMSINCKIA.
  • Molecular weight: 180.17
  • Formula: C7H8N4O2
  • CLOGP: -0.03
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 1
  • TPSA: 69.30
  • ALOGS: -0.80
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O
0.40 g P
0.40 g R
0.60 g O
0.60 g P
0.60 g R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 8.30 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 18 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 48.12 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.51 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.86 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.61 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 7.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
April 19, 1940 FDA GD SEARLE LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Asthma 774.57 12.88 516 22376 108456 53217718
Wheezing 348.51 12.88 260 22632 65015 53261159
Chronic obstructive pulmonary disease 178.29 12.88 172 22720 60901 53265273
Productive cough 143.82 12.88 148 22744 56581 53269593
Dyspnoea 138.58 12.88 556 22336 585676 52740498
Forced expiratory volume decreased 104.35 12.88 50 22842 5535 53320639
Sputum discoloured 104.03 12.88 69 22823 14270 53311904
Breath sounds abnormal 103.55 12.88 57 22835 8420 53317754
Rales 100.76 12.88 61 22831 10771 53315403
Sinus tachycardia 97.74 12.88 81 22811 23491 53302683
Rheumatoid arthritis 85.16 12.88 16 22876 314515 53011659
Chest discomfort 81.22 12.88 150 22742 99545 53226629
Hypercapnia 76.08 12.88 39 22853 4988 53321186
Bronchial neoplasm 74.19 12.88 20 22872 404 53325770
Nasal congestion 70.55 12.88 100 22792 53187 53272987
Bronchial haemorrhage 70.15 12.88 20 22872 500 53325674
Status asthmaticus 69.89 12.88 23 22869 939 53325235
Nasal turbinate hypertrophy 68.86 12.88 21 22871 667 53325507
Obstructive airways disorder 62.27 12.88 55 22837 17374 53308800
Cough 59.70 12.88 243 22649 256650 53069524
Endometrial ablation 59.40 12.88 20 22872 877 53325297
Sleep disorder due to a general medical condition 56.80 12.88 37 22855 7420 53318754
Bronchial disorder 56.79 12.88 21 22871 1215 53324959
Heart sounds 56.42 12.88 17 22875 518 53325656
Bronchitis chronic 55.83 12.88 30 22862 4224 53321950
Toxicity to various agents 55.25 12.88 213 22679 219385 53106789
Prolonged expiration 53.63 12.88 17 22875 615 53325559
Rhonchi 51.80 12.88 24 22868 2462 53323712
Neurosensory hypoacusis 51.37 12.88 14 22878 295 53325879
Alopecia 50.13 12.88 19 22873 234564 53091610
Pulmonary pain 47.36 12.88 22 22870 2270 53323904
Multiple drug therapy 46.55 12.88 19 22873 1434 53324740
Occupational asthma 45.69 12.88 11 22881 138 53326036
Lower respiratory tract infection 44.14 12.88 111 22781 90870 53235304
Pneumonia 43.46 12.88 311 22581 406858 52919316
Airway peak pressure increased 42.51 12.88 12 22880 289 53325885
Joint swelling 42.40 12.88 24 22868 234614 53091560
Systemic lupus erythematosus 42.21 12.88 3 22889 125411 53200763
Exercise tolerance decreased 42.11 12.88 27 22865 5268 53320906
Respiratory rate increased 42.10 12.88 38 22854 12345 53313829
Drug interaction 39.94 12.88 193 22699 219136 53107038
Respiratory acidosis 39.82 12.88 28 22864 6360 53319814
PCO2 increased 38.96 12.88 16 22876 1227 53324947
Acute respiratory failure 38.92 12.88 57 22835 31201 53294973
Lung hyperinflation 38.70 12.88 16 22876 1248 53324926
Increased viscosity of bronchial secretion 37.16 12.88 11 22881 315 53325859
Emphysema 36.72 12.88 32 22860 9927 53316247
Pain 36.52 12.88 130 22762 588268 52737906
Treatment failure 35.85 12.88 6 22886 128397 53197777
Fatigue 35.71 12.88 177 22715 730329 52595845
Oesophageal dilatation 35.64 12.88 11 22881 364 53325810
Granuloma 35.52 12.88 23 22869 4565 53321609
Dyspnoea exertional 35.38 12.88 75 22817 54925 53271249
Respiratory failure 35.28 12.88 109 22783 100403 53225771
Bronchial obstruction 35.28 12.88 16 22876 1562 53324612
Tachycardia 34.93 12.88 114 22778 108098 53218076
Lipohypertrophy 34.83 12.88 13 22879 772 53325402
Decreased bronchial secretion 34.80 12.88 8 22884 81 53326093
Middle insomnia 34.72 12.88 32 22860 10676 53315498
Bronchospasm 34.46 12.88 39 22853 16559 53309615
Blood pressure inadequately controlled 34.09 12.88 23 22869 4888 53321286
Respiration abnormal 33.97 12.88 24 22868 5494 53320680
Rash 33.75 12.88 90 22802 446101 52880073
Rhinitis 33.34 12.88 29 22863 8972 53317202
Eosinophilic granulomatosis with polyangiitis 33.10 12.88 17 22875 2182 53323992
Depressed mood 33.10 12.88 58 22834 36906 53289268
Contraindicated product administered 32.45 12.88 9 22883 135620 53190554
PO2 decreased 32.07 12.88 15 22877 1572 53324602
Depressive symptom 31.95 12.88 19 22873 3245 53322929
Congestive cardiomyopathy 31.68 12.88 24 22868 6114 53320060
Vital capacity decreased 31.30 12.88 13 22879 1026 53325148
Respiratory tract inflammation 30.87 12.88 11 22881 572 53325602
Arteriosclerosis coronary artery 30.84 12.88 27 22865 8427 53317747
Stress cardiomyopathy 30.54 12.88 27 22865 8535 53317639
Female sterilisation 30.32 12.88 11 22881 603 53325571
Synovitis 30.21 12.88 5 22887 107888 53218286
Adrenal suppression 28.73 12.88 12 22880 960 53325214
Blood bicarbonate decreased 28.36 12.88 17 22875 2945 53323229
Infective exacerbation of chronic obstructive airways disease 28.30 12.88 13 22879 1307 53324867
Blood pH decreased 27.56 12.88 16 22876 2614 53323560
Respiratory disorder 27.34 12.88 51 22841 34046 53292128
Affective disorder 27.14 12.88 21 22871 5518 53320656
Breast neoplasm 27.12 12.88 13 22879 1439 53324735
Product use issue 27.08 12.88 13 22879 139571 53186603
Asthmatic crisis 27.03 12.88 14 22878 1829 53324345
Antasthmatic drug level above therapeutic 27.02 12.88 4 22888 0 53326174
Diabetes mellitus inadequate control 26.98 12.88 32 22860 14278 53311896
Off label use 26.87 12.88 108 22784 472104 52854070
Sinus pain 26.82 12.88 15 22877 2284 53323890
Drug level increased 26.53 12.88 38 22854 20383 53305791
Arthropathy 26.21 12.88 14 22878 141439 53184735
Drug level above therapeutic 26.09 12.88 18 22874 3966 53322208
Eosinophil count increased 26.01 12.88 26 22866 9586 53316588
Viral infection 25.52 12.88 48 22844 32247 53293927
Infusion related reaction 25.34 12.88 18 22874 155939 53170235
Ligament pain 24.55 12.88 7 22885 175 53325999
Drug ineffective 24.42 12.88 229 22663 817016 52509158
Blood immunoglobulin E increased 24.38 12.88 14 22878 2241 53323933
Heart rate increased 24.15 12.88 84 22808 82231 53243943
Hepatic enzyme increased 24.11 12.88 12 22880 126183 53199991
Dyspnoea at rest 24.06 12.88 17 22875 3890 53322284
Swelling 23.98 12.88 28 22864 191077 53135097
Rhabdomyolysis 23.86 12.88 56 22836 43867 53282307
Medication error 23.85 12.88 50 22842 36315 53289859
Left ventricular failure 23.51 12.88 19 22873 5314 53320860
Diabetes mellitus 23.30 12.88 63 22829 53836 53272338
Kyphosis 22.71 12.88 14 22878 2550 53323624
Neutropenia 22.59 12.88 21 22871 159164 53167010
Hypoventilation 22.43 12.88 17 22875 4332 53321842
Painful respiration 22.10 12.88 14 22878 2676 53323498
Appetite disorder 22.08 12.88 20 22872 6523 53319651
Urogenital haemorrhage 21.90 12.88 7 22885 260 53325914
Drug intolerance 21.84 12.88 34 22858 205459 53120715
Cyanosis 21.67 12.88 31 22861 16608 53309566
Blood lactic acid increased 21.62 12.88 19 22873 5959 53320215
Febrile neutropenia 21.57 12.88 9 22883 104927 53221247
Respiratory tract congestion 21.56 12.88 29 22863 14670 53311504
Pleural rub 21.37 12.88 5 22887 55 53326119
Abdominal discomfort 21.26 12.88 39 22853 221023 53105151
Macrocytosis 21.25 12.88 13 22879 2337 53323837
Eosinophilia 21.11 12.88 35 22857 21300 53304874
Spleen congestion 21.04 12.88 6 22886 150 53326024
Glossitis 20.80 12.88 14 22878 2962 53323212
Presbyacusis 20.74 12.88 14 22878 2978 53323196
Lung opacity 20.73 12.88 12 22880 1949 53324225
Allergic cough 20.04 12.88 8 22884 570 53325604
Eye paraesthesia 19.88 12.88 5 22887 76 53326098
Therapeutic product effect decreased 19.76 12.88 15 22877 125640 53200534
Diarrhoea 19.63 12.88 173 22719 625373 52700801
Pertussis 19.55 12.88 8 22884 608 53325566
Bronchitis 19.28 12.88 97 22795 111802 53214372
Paranasal sinus hypersecretion 19.25 12.88 14 22878 3352 53322822
Musculoskeletal stiffness 19.05 12.88 15 22877 123353 53202821
Tremor 18.92 12.88 105 22787 125631 53200543
Oxygen saturation decreased 18.89 12.88 74 22818 76651 53249523
Oesophagogastroduodenoscopy 18.06 12.88 5 22887 112 53326062
Hypokalaemia 17.57 12.88 85 22807 96432 53229742
Contraindicated product prescribed 17.50 12.88 8 22884 796 53325378
Seizure 17.44 12.88 105 22787 129404 53196770
Ventricular tachycardia 17.38 12.88 29 22863 17733 53308441
Influenza 17.37 12.88 84 22808 95295 53230879
Myopathy 17.17 12.88 21 22871 9671 53316503
Rhinorrhoea 16.87 12.88 56 22836 53522 53272652
Sputum abnormal 16.75 12.88 7 22885 561 53325613
Stress urinary incontinence 16.66 12.88 11 22881 2256 53323918
Pulmonary congestion 16.65 12.88 27 22865 16129 53310045
Anaphylactic reaction 16.65 12.88 59 22833 58267 53267907
Oligoarthritis 16.64 12.88 5 22887 151 53326023
Haemoptysis 16.61 12.88 37 22855 28002 53298172
Increased bronchial secretion 16.58 12.88 10 22882 1753 53324421
Food allergy 16.53 12.88 19 22873 8199 53317975
Nasal oedema 16.00 12.88 8 22884 970 53325204
Injection site hypoaesthesia 15.80 12.88 6 22886 374 53325800
Respiratory tract infection 15.54 12.88 40 22852 33184 53292990
Oropharyngeal candidiasis 15.53 12.88 8 22884 1033 53325141
Discomfort 15.52 12.88 11 22881 95461 53230713
Depressed level of consciousness 15.49 12.88 55 22837 54373 53271801
Staphylococcus test positive 15.41 12.88 13 22879 3860 53322314
Aortic valve calcification 15.40 12.88 6 22886 401 53325773
Status epilepticus 15.14 12.88 25 22867 15159 53311015
Stomatitis 15.07 12.88 12 22880 98146 53228028
Chest pain 14.62 12.88 135 22757 190050 53136124
Blood count abnormal 14.58 12.88 29 22863 20286 53305888
Atopy 14.34 12.88 5 22887 244 53325930
Wrong technique in product usage process 14.32 12.88 4 22888 60028 53266146
Neonatal tachycardia 14.29 12.88 3 22889 19 53326155
Dysphonia 14.26 12.88 45 22847 41893 53284281
Hypercholesterolaemia 14.25 12.88 22 22870 12604 53313570
Scratch 14.17 12.88 14 22878 5090 53321084
Crepitations 14.13 12.88 16 22876 6793 53319381
Impaired healing 14.03 12.88 5 22887 64200 53261974
Generalised tonic-clonic seizure 13.84 12.88 35 22857 28723 53297451
Parakeratosis 13.71 12.88 5 22887 278 53325896
Escherichia infection 13.61 12.88 21 22871 12029 53314145
Supraventricular tachycardia 13.50 12.88 23 22869 14302 53311872
Cushingoid 13.44 12.88 16 22876 7166 53319008
Mental disability 13.40 12.88 4 22888 118 53326056
Peripheral swelling 13.08 12.88 45 22847 206063 53120111
Death 12.91 12.88 95 22797 357137 52969037

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Asthma 561.66 13.27 310 14491 43755 32454970
Chronic obstructive pulmonary disease 317.43 13.27 224 14577 48529 32450196
Wheezing 167.90 13.27 137 14664 36737 32461988
Forced expiratory volume decreased 130.12 13.27 52 14749 3504 32495221
Obstructive airways disorder 119.50 13.27 72 14729 11889 32486836
Dyspnoea 107.26 13.27 384 14417 361661 32137064
Vital capacity decreased 71.84 13.27 20 14781 430 32498295
Productive cough 66.81 13.27 80 14721 34036 32464689
Respiratory failure 65.35 13.27 148 14653 107034 32391691
Right atrial hypertrophy 63.15 13.27 17 14784 321 32498404
Bronchial wall thickening 60.66 13.27 21 14780 944 32497781
Foetal malformation 55.14 13.27 13 14788 139 32498586
Mental disability 54.44 13.27 10 14791 25 32498700
Sputum discoloured 51.75 13.27 36 14765 7580 32491145
Bronchial secretion retention 51.18 13.27 19 14782 1047 32497678
Forced vital capacity decreased 49.26 13.27 17 14784 757 32497968
Trisomy 18 48.77 13.27 13 14788 236 32498489
Cough 46.65 13.27 154 14647 138663 32360062
Right ventricular hypertrophy 45.96 13.27 17 14784 927 32497798
Pulmonary function test decreased 44.70 13.27 28 14773 4947 32493778
Obstruction 41.11 13.27 19 14782 1826 32496899
Aortic valve stenosis 40.97 13.27 20 14781 2172 32496553
Tachycardia foetal 40.61 13.27 12 14789 321 32498404
Gastrooesophageal reflux disease 39.97 13.27 63 14738 34675 32464050
Chest X-ray abnormal 39.66 13.27 24 14777 3989 32494736
Sleep disorder due to a general medical condition 38.36 13.27 22 14779 3312 32495413
Therapeutic product effect incomplete 38.26 13.27 68 14733 41273 32457452
Foetal distress syndrome 36.65 13.27 15 14786 1074 32497651
Diastolic dysfunction 36.21 13.27 25 14776 5199 32493526
Pulmonary function test abnormal 35.92 13.27 18 14783 2068 32496657
Eosinophil count increased 35.79 13.27 30 14771 8325 32490400
Eosinophilic granulomatosis with polyangiitis 35.24 13.27 16 14785 1476 32497249
Total lung capacity abnormal 33.43 13.27 9 14792 170 32498555
Supraventricular tachycardia 32.59 13.27 32 14769 10884 32487841
Dyspnoea exertional 30.92 13.27 60 14741 38901 32459824
Chest discomfort 30.15 13.27 69 14732 50161 32448564
Blood count abnormal 29.81 13.27 33 14768 12893 32485832
Pneumonia 29.48 13.27 268 14533 354984 32143741
Atrial fibrillation 28.64 13.27 117 14684 116587 32382138
Loss of personal independence in daily activities 28.59 13.27 47 14754 26786 32471939
Tachycardia 28.56 13.27 90 14711 78998 32419727
Blood immunoglobulin E increased 27.55 13.27 15 14786 2042 32496683
Wolff-Parkinson-White syndrome 27.29 13.27 8 14793 208 32498517
Sputum increased 26.83 13.27 15 14786 2150 32496575
Emphysema 25.87 13.27 27 14774 9870 32488855
Bronchiectasis 25.68 13.27 23 14778 6969 32491756
Intervertebral disc degeneration 25.44 13.27 21 14780 5703 32493022
Lung hyperinflation 25.08 13.27 11 14790 935 32497790
Full blood count abnormal 24.88 13.27 16 14785 2957 32495768
Supraventricular extrasystoles 23.25 13.27 16 14785 3309 32495416
Arrhythmia 22.86 13.27 50 14751 35253 32463472
Off label use 22.78 13.27 68 14733 306252 32192473
Conduction disorder 22.54 13.27 13 14788 1977 32496748
Hypercapnia 22.30 13.27 17 14784 4118 32494607
Rhinitis perennial 21.51 13.27 6 14795 130 32498595
Hypoxia 21.32 13.27 62 14739 52070 32446655
Osteoporosis 21.30 13.27 27 14774 12155 32486570
Diarrhoea 21.13 13.27 90 14711 364712 32134013
Tachyarrhythmia 20.63 13.27 15 14786 3384 32495341
Eosinophilic bronchitis 20.40 13.27 6 14795 158 32498567
Status asthmaticus 19.47 13.27 7 14794 352 32498373
Febrile neutropenia 18.89 13.27 16 14785 119550 32379175
Bronchial obstruction 18.86 13.27 11 14790 1708 32497017
Epidural lipomatosis 18.59 13.27 8 14793 649 32498076
Tonic convulsion 18.58 13.27 9 14792 961 32497764
Drug level increased 18.52 13.27 33 14768 20047 32478678
Ventricular extrasystoles 18.46 13.27 25 14776 12001 32486724
Unmasking of previously unidentified disease 18.01 13.27 8 14793 701 32498024
Neutropenia 17.99 13.27 23 14778 142152 32356573
Carbon dioxide increased 17.86 13.27 9 14792 1046 32497679
Lung opacity 17.72 13.27 10 14791 1460 32497265
Perfume sensitivity 17.44 13.27 5 14796 120 32498605
Pancytopenia 17.33 13.27 10 14791 91225 32407500
Lipid metabolism disorder 17.03 13.27 6 14795 284 32498441
Somnambulism 16.80 13.27 13 14788 3219 32495506
Benign prostatic hyperplasia 16.45 13.27 24 14777 12340 32486385
Sleep apnoea syndrome 16.19 13.27 30 14771 18784 32479941
Gastrointestinal necrosis 16.02 13.27 13 14788 3446 32495279
Vitamin D increased 15.31 13.27 4 14797 67 32498658
Gout 15.04 13.27 29 14772 18699 32480026
Product use in unapproved indication 14.61 13.27 11 14790 87193 32411532
Nikolsky's sign 14.37 13.27 5 14796 228 32498497
Accelerated idioventricular rhythm 14.28 13.27 4 14797 88 32498637
Bronchospasm 14.19 13.27 21 14780 10934 32487791
Electrocardiogram repolarisation abnormality 14.12 13.27 7 14794 786 32497939
Diverticulum intestinal haemorrhagic 14.04 13.27 10 14791 2184 32496541
Sputum purulent 13.81 13.27 6 14795 498 32498227
Circulatory collapse 13.76 13.27 30 14771 21095 32477630
Death 13.75 13.27 110 14691 382407 32116318
Ocular discomfort 13.74 13.27 9 14792 1715 32497010
Discoloured vomit 13.63 13.27 6 14795 514 32498211
Ventricular arrhythmia 13.53 13.27 14 14787 5065 32493660
Fatigue 13.47 13.27 99 14702 350602 32148123
Small intestinal perforation 13.39 13.27 9 14792 1790 32496935
Therapeutic product effect prolonged 13.39 13.27 5 14796 280 32498445

Pharmacologic Action:

SourceCodeDescription
ATC R03DA04 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xanthines
ATC R03DA05 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xanthines
ATC R03DA54 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xanthines
ATC R03DA55 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xanthines
ATC R03DA74 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xanthines
ATC R03DB04 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xanthines and adrenergics
ATC R03DB05 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xanthines and adrenergics
FDA CS M0023046 Xanthines
CHEBI has role CHEBI:35523 bronchodilator agents
CHEBI has role CHEBI:38147 cardiotonic drugs
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D001993 Bronchodilator Agents
MeSH PA D002316 Cardiotonic Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D010726 Phosphodiesterase Inhibitors
MeSH PA D020011 Protective Agents
MeSH PA D058914 Purinergic Antagonists
MeSH PA D058915 Purinergic P1 Receptor Antagonists
MeSH PA D019141 Respiratory System Agents
MeSH PA D014665 Vasodilator Agents
FDA EPC N0000175790 Methylxanthine
CHEBI has role CHEBI:35620 vasodilator
CHEBI has role CHEBI:49103 drug metabolites
CHEBI has role CHEBI:49167 anti-asthmatic agents
CHEBI has role CHEBI:50218 phosphodiesterase inhibitors
CHEBI has role CHEBI:50846 Biomodulator
CHEBI has role CHEBI:51371 muscle relaxants
CHEBI has role CHEBI:67079 antiinflammatory agents
CHEBI has role CHEBI:71232 adenosine receptor antagonists
CHEBI has role CHEBI:76946 fungal metabolites
CHEBI has role CHEBI:85234 human blood serum metabolites

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Bronchospasm indication 4386001
Disorder of lung indication 19829001 DOID:850
Bronchitis indication 32398004 DOID:6132
Pulmonary emphysema indication 87433001
Asthma indication 195967001 DOID:2841
Asthma night-time symptoms indication 395022009
Asthma management indication 406162001
Acute exacerbation of asthma indication 708038006
Asthma-chronic obstructive pulmonary disease overlap syndrome indication 10692761000119107
COPD Associated with Chronic Bronchitis indication
Chronic Obstructive Pulmonary Disease with Bronchospasms indication
Apnea in the newborn off-label use 13094009
Neonatal Mixed Apnea off-label use
Goiter contraindication 3716002 DOID:12176
Tachyarrhythmia contraindication 6285003
Suicidal thoughts contraindication 6471006
Alcoholism contraindication 7200002
Hyperammonemia contraindication 9360008
Peptic ulcer contraindication 13200003 DOID:750
Hepatic encephalopathy contraindication 13920009 DOID:13413
Hyperkalemia contraindication 14140009
Pulmonary edema contraindication 19242006 DOID:11396
Hashimoto thyroiditis contraindication 21983002
Myocardial infarction contraindication 22298006 DOID:5844
Acute tuberculosis contraindication 25629007
Shock contraindication 27942005
Hyperthyroidism contraindication 34486009 DOID:7998
Depressive disorder contraindication 35489007
Acute hepatitis contraindication 37871000
Hypertensive disorder contraindication 38341003 DOID:10763
Hypothyroidism contraindication 40930008 DOID:1459
Third trimester pregnancy contraindication 41587001
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Coronary arteriosclerosis contraindication 53741008 DOID:3393
Multiple organ failure contraindication 57653000
Hepatic failure contraindication 59927004
Poisoning by phenobarbital contraindication 64921004
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Sleep apnea contraindication 73430006 DOID:0050847
Chronic idiopathic constipation contraindication 82934008
Cor pulmonale contraindication 83291003 DOID:8515
Open-angle glaucoma contraindication 84494001 DOID:1067
Kidney disease contraindication 90708001 DOID:557
Dermatitis herpetiformis contraindication 111196000 DOID:8505
Seizure disorder contraindication 128613002
Cystic fibrosis contraindication 190905008 DOID:1485
Angina pectoris contraindication 194828000
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Sepsis syndrome contraindication 238150007
Hypocomplementemic urticarial vasculitis contraindication 239945009
Benign prostatic hyperplasia contraindication 266569009
Dyspnea contraindication 267036007
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Continuous fever contraindication 271751000
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Smoking cessation assistance contraindication 384742004
Angle-closure glaucoma contraindication 392291006 DOID:13550
Breastfeeding (mother) contraindication 413712001
Chronic myocardial ischemia contraindication 413844008 DOID:3393
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Porphyria contraindication 418470004
Hypertensive urgency contraindication 443482000
Smokes tobacco daily contraindication 449868002
Severe Hypoxemia contraindication
Theophylline Toxicity contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.46 acidic
pKa2 3.01 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
cGMP-inhibited 3',5'-cyclic phosphodiesterase A Enzyme INHIBITOR Ki 3.85 WOMBAT-PK CHEMBL
cAMP-specific 3',5'-cyclic phosphodiesterase 4A Enzyme INHIBITOR Ki 4.11 WOMBAT-PK CHEMBL
Adenosine receptor A1 GPCR ANTAGONIST Ki 9.22 CHEMBL CHEMBL
Adenosine receptor A2b GPCR ANTAGONIST Ki 5.57 CHEMBL CHEMBL
Adenosine receptor A2a GPCR ANTAGONIST Ki 9.22 CHEMBL CHEMBL
Transmembrane domain-containing protein TMIGD3 Unclassified Ki 4.06 CHEMBL
Adenosine receptor A3 GPCR ANTAGONIST Ki 7.85 CHEMBL
Alkaline phosphatase, tissue-nonspecific isozyme Enzyme Ki 4.09 CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Kinase IC50 4.12 CHEMBL
Adenosine receptor A2a GPCR Ki 5.17 CHEMBL
Uncharacterized protein Enzyme Ki 4.11 CHEMBL
Adenosine receptor A3 GPCR Ki 4.07 CHEMBL
Adenosine receptor A1 GPCR Ki 5.42 CHEMBL
Adenosine receptor A1 GPCR Ki 5.01 CHEMBL
Adenosine A2 receptor GPCR Ki 5.88 CHEMBL
Adenosine A2b receptor GPCR Ki 4.82 CHEMBL
Adenosine receptor GPCR Ki 4.70 CHEMBL
Heart phosphodiesterase Enzyme IC50 4.04 CHEMBL
Adenosine A2a receptor GPCR Ki 4.89 CHEMBL
Adenosine receptor A2b GPCR ANTAGONIST Ki 5.25 IUPHAR
Adenosine receptor A1 GPCR Ki 6.15 CHEMBL

External reference:

IDSource
4018056 VUID
N0000146397 NUI
D00227 KEGG_DRUG
4018055 VANDF
4018056 VANDF
4018129 VANDF
4018130 VANDF
4018132 VANDF
C0039771 UMLSCUI
CHEBI:28177 CHEBI
TEP PDB_CHEM_ID
CHEMBL190 ChEMBL_ID
DB00277 DRUGBANK_ID
CHEMBL1370561 ChEMBL_ID
D013806 MESH_DESCRIPTOR_UI
2153 PUBCHEM_CID
413 IUPHAR_LIGAND_ID
376 INN_ID
5967-84-0 SECONDARY_CAS_RN
C137DTR5RG UNII
DB01223 DRUGBANK_ID
10438 RXNORM
2086 MMSL
3058 MMSL
4172 MMSL
4173 MMSL
4175 MMSL
5563 MMSL
5564 MMSL
674 MMSL
72114 MMSL
72147 MMSL
d00142 MMSL
d00758 MMSL
000602 NDDF
000603 NDDF
000607 NDDF
000608 NDDF
111131008 SNOMEDCT_US
372810006 SNOMEDCT_US
373508009 SNOMEDCT_US
387431001 SNOMEDCT_US
45940009 SNOMEDCT_US
55867006 SNOMEDCT_US
66493003 SNOMEDCT_US
D000628 MESH_DESCRIPTOR_UI
D031210 MESH_DESCRIPTOR_UI
CHEMBL1200578 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
THEOPHYLLINE HUMAN PRESCRIPTION DRUG LABEL 1 0121-0820 SOLUTION 80 mg ORAL ANDA 25 sections
Theophylline HUMAN PRESCRIPTION DRUG LABEL 1 0121-4794 SOLUTION 80 mg ORAL ANDA 25 sections
THEOPHYLLINE HUMAN PRESCRIPTION DRUG LABEL 1 0121-4820 SOLUTION 80 mg ORAL ANDA 25 sections
Theophylline in Dextrose HUMAN PRESCRIPTION DRUG LABEL 2 0264-9554 INJECTION, SOLUTION 80 mg INTRAVENOUS NDA 27 sections
Theophylline(Anhydrous) HUMAN PRESCRIPTION DRUG LABEL 1 0378-0486 TABLET, EXTENDED RELEASE 400 mg ORAL ANDA 22 sections
Theophylline(Anhydrous) HUMAN PRESCRIPTION DRUG LABEL 1 0378-0487 TABLET, EXTENDED RELEASE 600 mg ORAL ANDA 22 sections
Aminophylline HUMAN PRESCRIPTION DRUG LABEL 1 0404-9813 INJECTION, SOLUTION 25 mg INTRAVENOUS ANDA 12 sections
Aminophylline HUMAN PRESCRIPTION DRUG LABEL 1 0404-9814 INJECTION, SOLUTION 25 mg INTRAVENOUS ANDA 12 sections
Aminophylline HUMAN PRESCRIPTION DRUG LABEL 1 0409-5921 INJECTION, SOLUTION 25 mg INTRAVENOUS ANDA 22 sections
Aminophylline HUMAN PRESCRIPTION DRUG LABEL 1 0409-5922 INJECTION, SOLUTION 25 mg INTRAVENOUS ANDA 22 sections
Theophylline Extended Release HUMAN PRESCRIPTION DRUG LABEL 1 0615-1590 TABLET, EXTENDED RELEASE 300 mg ORAL ANDA 23 sections
Theophylline Extended Release HUMAN PRESCRIPTION DRUG LABEL 1 0615-2503 TABLET, EXTENDED RELEASE 200 mg ORAL ANDA 23 sections
Theophylline HUMAN PRESCRIPTION DRUG LABEL 1 10135-604 SOLUTION 80 mg ORAL ANDA 22 sections
Theophylline HUMAN PRESCRIPTION DRUG LABEL 1 17856-0038 SOLUTION 80 mg ORAL ANDA 13 sections
ELIXOPHYLLIN Human Prescription Drug Label 1 17856-0644 LIQUID 80 mg ORAL ANDA 21 sections
Theophylline HUMAN PRESCRIPTION DRUG LABEL 1 27808-033 SOLUTION 80 mg ORAL ANDA 13 sections
Theophylline(Anhydrous) HUMAN PRESCRIPTION DRUG LABEL 1 29033-001 TABLET, EXTENDED RELEASE 400 mg ORAL ANDA 22 sections
Theophylline(Anhydrous) HUMAN PRESCRIPTION DRUG LABEL 1 29033-002 TABLET, EXTENDED RELEASE 600 mg ORAL ANDA 22 sections
TheophyllineAnhydrous HUMAN PRESCRIPTION DRUG LABEL 1 42858-701 TABLET, EXTENDED RELEASE 400 mg ORAL ANDA 25 sections
TheophyllineAnhydrous HUMAN PRESCRIPTION DRUG LABEL 1 42858-702 TABLET, EXTENDED RELEASE 600 mg ORAL ANDA 25 sections
Theophylline Human Prescription Drug Label 1 46708-025 TABLET, EXTENDED RELEASE 300 mg ORAL ANDA 21 sections
Theophylline Human Prescription Drug Label 1 46708-026 TABLET, EXTENDED RELEASE 450 mg ORAL ANDA 21 sections
Theophylline(Anhydrous) HUMAN PRESCRIPTION DRUG LABEL 1 51407-318 TABLET, EXTENDED RELEASE 400 mg ORAL ANDA 22 sections
Theophylline(Anhydrous) HUMAN PRESCRIPTION DRUG LABEL 1 51407-319 TABLET, EXTENDED RELEASE 600 mg ORAL ANDA 22 sections
AMINOPHYLLINE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1204 INJECTION, SOLUTION 25 mg INTRAVENOUS ANDA 12 sections
AMINOPHYLLINE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1341 INJECTION, SOLUTION 25 mg INTRAVENOUS ANDA 12 sections
Theo-24 HUMAN PRESCRIPTION DRUG LABEL 1 52244-100 CAPSULE, EXTENDED RELEASE 100 mg ORAL ANDA 25 sections
Theo-24 HUMAN PRESCRIPTION DRUG LABEL 1 52244-200 CAPSULE, EXTENDED RELEASE 200 mg ORAL ANDA 25 sections
Theo-24 HUMAN PRESCRIPTION DRUG LABEL 1 52244-300 CAPSULE, EXTENDED RELEASE 300 mg ORAL ANDA 25 sections
Theo-24 HUMAN PRESCRIPTION DRUG LABEL 1 52244-400 CAPSULE, EXTENDED RELEASE 400 mg ORAL ANDA 25 sections